Abstract: This invention provides novel phenyl and heterocyclic derivatives, their pharmaceutical formulations and their use for antagonizing angiotensin II receptors in mammals.
Type:
Grant
Filed:
May 30, 1995
Date of Patent:
October 8, 1996
Assignee:
Eli Lilly and Company
Inventors:
Sherryl L. Lifer, Winston S. Marshall, Fariborz Mohamadi, Jon K. Reel, Richard L. Simon, Mitchell I. Steinberg, Celia A. Whitesitt
Abstract: This invention provides novel heterocyclic derivatives, their pharmaceutical formulations, and their use for antagonizing angiotensin II receptors in mammals.
Type:
Grant
Filed:
May 30, 1995
Date of Patent:
September 17, 1996
Assignee:
Eli Lilly and Company
Inventors:
Donald B. Boyd, Sherryl L. Lifer, Winston S. Marshall, Alan D. Palkowitz, William Pfeifer, Jon K. Reel, Richard L. Simon, Mitchell I. Steinberg, K. Jeff Thrasher, Venkatraghaven Vasudevan, Celia A. Whitesitt
Abstract: Provided are compounds of the formula II ##STR1## wherein R.sub.6 and R.sub.7 are independently hydrogen or C.sub.1 -C.sub.6 alkyl;R.sub.5 is naphthyl, substituted nephthyl, or phenyl substituted one to three times with C.sub.1 -C.sub.6 alkoxy, C.sub.1 -C.sub.6 alkyl, phenyl, or hydroxy; with the proviso that if the phenyl is substituted once with hydroxy, it must be further be substituted once or twice with C.sub.1 -C.sub.6 alkoxy, C.sub.l -C.sub.6 alkyl, phenyl or hydroxy, and pharmaceutically acceptable salts thereof.
Type:
Grant
Filed:
March 13, 1995
Date of Patent:
July 2, 1996
Assignee:
Eli Lilly and Company
Inventors:
Donald G. Carlson, George J. Cullinan, Kennan J. Fahey, William T. Jackson, Neal W. Roehm, Stephen M. Spaethe
Abstract: A method for modulating calcium channels, increasing the density of calcium channels in vascular and cardiac tissue with no changes in inotropic or pressor response, comprising administering to a warm-blooded animal in need thereof a pharmaceutically-effective amount of a compound having the formula ##STR1## wherein R.sup.1 and R.sup.3 are independently hydrogen, C.sub.1 -C.sub.4 alkyl, --CO--(C.sub.1 -C.sub.6 alkyl), or --CH.sub.2 Ar, --CO--Ar, wherein Ar is phenyl or substituted phenyl;R.sup.2 is selected from the group consisting of pyrrolidine, hexamethylenemino, and piperidino; or a pharmaceutically-acceptable salt thereof.
Abstract: A method of inhibiting 5-lipoxygenase comprising administering to a mammal in need thereof an effective amount of a compound having the formula ##STR1## wherein R.sub.1 and R.sub.2 are independently hydrogen or C.sub.1 -C.sub.6 alkyl;R.sub.3 is hydrogen, or a group of the formula ##STR2## wherein R.sub.4 phenyl, substituted phenyl, naphthyl or substituted naphthyl, with the proviso that when R.sub.1 and R.sub.2 are both C.sub.1 -C.sub.6 alkyl, R.sub.3 is not hydrogen; and pharmaceutically acceptable salts thereof.
Type:
Grant
Filed:
March 13, 1995
Date of Patent:
May 7, 1996
Assignee:
Eli Lilly and Company
Inventors:
Donald G. Carlson, George J. Cullinan, Kennan J. Fahey, William T. Jackson, Neal W. Roehm, Stephen M. Spaethe
Abstract: A method of inhibiting leukotrienes comprising administering to a mammal in need thereof an effective amount of a compound having the formula ##STR1## wherein R.sub.1 and R.sub.2 are independently hydrogen or C.sub.1 -C.sub.6 alkyl;R.sub.3 is hydrogen, or a group of the formula ##STR2## wherein R.sub.4 is phenyl, substituted phenyl, naphthyl or substituted naphthyl, with the proviso that when R.sub.1 and R.sub.2 are both C.sub.1 -C.sub.6 alkyl, R.sub.3 is not hydrogen; and pharmaceutically acceptable salts thereof.
Type:
Grant
Filed:
March 13, 1995
Date of Patent:
May 7, 1996
Assignee:
Eli Lilly and Company
Inventors:
Donald G. Carlson, George J. Cullinan, Kennan J. Fahey, William T. Jackson, Neal W. Roehm, Stephen M. Spaethe
Abstract: The invention provides pharmaceutical compounds of the formula: ##STR1## in which A - - - B is CH.sub.2 --CH.sub.2 or CH.dbd.CH;X is a pyridine or benzene ring;when X is pyridine n is 0;when X is benzene n is 0, 1 or 2 and when A - - - B is CH.sub.2 --CH.sub.2, R.sup.1 is attached at any of the positions 7 to 10, and when A - - - B is CH.dbd.CH, R.sup.1 is attached at any of the positions 5 to 10;and salts thereof.
Abstract: This invention provides novel phenyl and heterocyclic derivatives, their pharmaceutical formulations and their methods of use for antagonizing angiotensin II receptors in mammals.
Type:
Grant
Filed:
December 14, 1994
Date of Patent:
January 16, 1996
Assignee:
Eli Lilly and Company
Inventors:
Donald B. Boyd, Kenneth L. Hauser, Sherryl L. Lifer, Winston S. Marshall, Alan D. Palkowitz, William Pfeifer, Jon K. Reel, Richard L. Simon, Mitchell I. Steinberg, Kumiko Takeuchi, K. Jeff Thrasher, Celia A. Whitesitt
Abstract: A full-length transcript promoter from figwort mosaic virus (FMV) is identified and its DNA sequence given. The promoter functions as a strong and uniform promoter for chimeric genes inserted into plant cells. This strong promoter function is exhibited by a histochemical assay in floral buds and by reproductive scores of transgenic plants including the promoter. The promoter preferably includes a 5' leader sequence that may be from the FMV itself or from a heterologous source with respect to the promoter. The promoter is used in a plant cassette vector, a chimeric gene and in methods for transforming plant cells to obtain transgenic plants, plant cells or seeds incorporating the FMV promoter.
Abstract: This invention provides DNA molecules which comprise 5' non-translated leader sequences derived from genes coding for heat shock proteins that enhance gene expression in plants when present in a chimeric gene. Plant cells and plants containing same are also provided herewith. Further provided is a method for enhancing gene expression in plants.
Abstract: A DNA sequence encoding a potato leafroll virus coat protein having at least one internal translation initiation codon in a different reading frame than the native PLRV coat protein DNA sequence altered to a non-initiator codon is provided. Two translation initiation sites at the start of a 17kd open reading frame in a different reading frame than the native PLRV coat protein DNA sequence are preferably altered A stronger stop codon is also provided in the modified PLRV DNA sequence. The modified DNA sequence having the internal translation initiation codons at the start of the 17kd open reading frame altered to non-initiator codons can be used in a gene to transform plants of the Solanaceae family to obtain transgenic plants resistant to PLRV. A synthetic modified potato leafroll virus DNA sequence is also provided which has the changes in the translation initiation sites and is further made to be more "plant-like".
Type:
Grant
Filed:
September 3, 1991
Date of Patent:
April 19, 1994
Assignee:
Monsanto Company
Inventors:
Edgar C. Lawson, James D. Weiss, Cynthia L. Hemenway, Nilgun E. Tumer